Organic compounds -- part of the class 532-570 series – Organic compounds – Chalcogen in the nitrogen containing substituent
Reexamination Certificate
2008-04-30
2011-12-06
Davis, Zinna Northington (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Chalcogen in the nitrogen containing substituent
C546S146000, C546S211000, C548S362500
Reexamination Certificate
active
08071762
ABSTRACT:
The present invention discloses novel compounds of general formula (I)or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2and Ar1are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
REFERENCES:
patent: 3647819 (1972-03-01), Kirchner et al.
patent: 3711610 (1973-01-01), Kirchner et al.
patent: 3814711 (1974-06-01), Eloy et al.
patent: 4958026 (1990-09-01), Schoellkopf et al.
patent: 5362878 (1994-11-01), Chang et al.
patent: 5444038 (1995-08-01), James et al.
patent: 5646140 (1997-07-01), Sugg et al.
patent: 5656634 (1997-08-01), Chang et al.
patent: 5760246 (1998-06-01), Biller et al.
patent: 6001860 (1999-12-01), Hamanaka
patent: 6291476 (2001-09-01), Kordik
patent: 6472414 (2002-10-01), Biller et al.
patent: 6511998 (2003-01-01), Kordik et al.
patent: 6555539 (2003-04-01), Reich et al.
patent: 6858577 (2005-02-01), Zhang et al.
patent: 6933311 (2005-08-01), Lee et al.
patent: 0587180 (1993-09-01), None
patent: 1256574 (2001-02-01), None
patent: 9850347 (1998-11-01), None
patent: 03014064 (2003-02-01), None
patent: 03014064 (2003-02-01), None
patent: 03055484 (2003-07-01), None
patent: 03055848 (2003-07-01), None
patent: WO-03055648 (2003-07-01), None
patent: 03070247 (2003-08-01), None
patent: 03080578 (2003-10-01), None
patent: 03097586 (2003-11-01), None
Landsiedel-Maier, D., “Structure activity relationship of homochiral 7-substituted 1-aminoindans as 5-HT1 A receptor ligands”, Archiv Der Pharmazie, vol. 331, 1998, pp. 59-71, XP002296522.
Sterling, J., “Novel dual inhibitors of AchE and MAO,” Journal for Medicinal Chemistry, vol. 45, No. 24, 2002, pp. 5260-5279, XP002296523.
Poste et al. “Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells”, Methods in Cell Biology, Academic Press, 1976, Chapter 4, vol. 14, 33-71.
Berge, et al. “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, vol. 66, No. 1 et seq. (1977).
Caterina, et al., “The capsaicin receptor: a heat-activated ion channel in the pain pathway,” Nature, vol. 389 (1997), pp. 816-824.
Caterina, et al., “The Vanilloid Receptor: A Molecular gateway to the pain pathway,” Annual Review of Neuroscience vol. 24 (2001), pp. 487-517.
Caterina, et al., “Impaired Nociception and pain sensation in mice lacking the capsaicin receptor,” Science, vol. 288, (2000), pp. 306-313.
Collier, et al., Br. J. Pharmacol. Chemother, vol. 32 (1968), pp. 295-310.
Davis, et al., “Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia,” Nature, vol. 405 (2000) pp. 183-187.
Fowler, et al., “Intravesical treatment of overactive bladder,” Urology, vol. 55, No. Supp 5A (2000), pp. 60-64.
Hayes, et al., “Cloning and functional expression of a human orthologue of rat vanilloid receptor-1,” Pain, vol. 88 (2000), pp. 205-215.
IUPAC 1974 Recommendation for Section E, Fundamental Sterochemistry, Pure App. Chem., vol. 45 (1976), pp. 13-30.
Landsiedel-Maier, “Structure Activity Relationship of Homonchiral 7-Substituted 1-Aminoindans as 5-HT1A Receptor Ligands,” Archie Der Pharmazie, vol. 331 (1998), pp. 59-71.
Nolano, et al., “Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation,” Pain, vol. 81 (1999), pp. 135-145.
Pircio, et al., “A New Method for the Evaluation of Analgesic Activity using Adjuvant-Induced Arthritis in the Rat” Eur J. Pharmacol. vol. 31, No. 2 (1975), pp. 207-215.
Prescott, et al., Methods in Cell Biology, Academic Press, New York, N.Y. vol. 14, No. 33 et seq. (1976).
Sterling, “Novel Dual Inhibitors of AchE and MAO,” Journal of Medicinal Chemistry, vol. 45, No. 24 (2002), pp. 5260-5279.
Thummel, et al., “Polyaza Cavity-Shaped Molecules. Annelated Derivatives of 2-(2′-Pyridyl)-1,8-naphthyridine and 2,2′-Bi-1,8-naphthyridine” J. Org. Chem., vol. 49 (1984) pp. 2208-2212.
Bayburt Erol K.
Chambournier Gilles
Cink Russell D.
Gomtsyan Arthur R.
Hsu Margaret Chi-Ping
Abbott Laboratories
Davis Zinna Northington
Michael & Best & Friedrich LLP
Mueller Lisa V.
LandOfFree
Fused compounds that inhibit vanilloid receptor subtype 1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused compounds that inhibit vanilloid receptor subtype 1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused compounds that inhibit vanilloid receptor subtype 1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4300129